In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum.

Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae K Feaster, Ksenia Blinova

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akshay NarkarCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0002-3649-1230

Abouzar KaboudianCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Yasaman ArdeshirpourCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Maura CasciolaCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Tromondae K FeasterCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Ksenia BlinovaCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0003-1123-3152

Funding

Center for Devices and Radiological Health NA

6 · The paper itself

Abstract

Exposing cells to intense and brief electric field pulses can modulate cell permeability, a phenomenon termed electroporation. When applied in medical treatments of diseases like cancer and cardiac arrhythmias, depending on level of cellular destruction, it is also referred to as irreversible electroporation (IRE) or Pulsed Field Ablation (PFA). For ablation device testing, several pulse parameters need to be characterized in a comprehensive manner to assess lesion boundary and efficacy. Overly aggressive voltages and application numbers increase animal burden. The potato tuber is a widely used initial model for the early testing of electroporation. The aim of this study is to characterize and refine bench testing for the ablation outcomes of PFA in this simplistic vegetal model. For in vitro assays, several pulse parameters like voltage, duration, and frequency were modulated to study effects not only on 2D ablation area but also 3D depth and volume. As PFA is a relatively new technology with minimal thermal effects, we also measured temperature changes before, during, and after ablation. Data from experiments were supplemented with in silico modeling to examine E-field distribution. We have estimated the irreversible electroporation threshold in

Indexed as

ElectroporationSolanum tuberosumAblation TechniquesComputer SimulationIrreversible Electroporation TherapyTemperatureelectroporationlesion depthpotatopulsed field ablationtuber model

Identifiers

PMID39201653

DOI10.3390/ijms25168967

PMCPMC11354718

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.